FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients self-identified as Black had an 18% lower bioavailability of ticagrelor compared to Caucasian patients.
Danish: Patienter, der selv opfatter sig som negroide, havde en 18 % lavere biotilgængelighed af ticagrelor sammenlignet med kaukasiske patienter.
English: If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or dentist before
Danish: Hvis et eller flere af ovennævnte udsagn gælder for dig (eller du er usikker), så tal med lægen, apoteket eller tandlægen, før du tager Possia.
English: Dyspnoea, a sensation of breathlessness, is reported by patients treated with Possia.
Danish: Der blev rapporteret dyspnø, en fornemmelse af åndenød, hos de patienter, der blev behandlet med Possia.
English: Do not use this medicine after the expiry date, which is stated on the blister and carton after EXP.
Danish: Brug ikke dette lægemiddel efter den udløbsdato, der står på blisterkortet og æsken efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned.
English: P-glycoprotein (P-gp) substrates (including digoxin, cyclosporin) Concomitant administration of Possia increased the digoxin Cmax by 75% and AUC by 28%.
Danish: P-glykoprotein (P-gp)-substrater (herunder digoxin, ciclosporin) Samtidig administration af Possia øgede digoxins Cmax med 75 % og AUC med 28 %.
English: Similar to the overall PLATO study, total PLATO Major bleeding did not differ between ticagrelor and clopidogrel, regardless of CYP2C19 or ABCB1 genotype.
Danish: I lighed med det overordnede PLATO-studie, var samlet PLATO Major Bleeding ikke forskellig ticagrelor og clopidogrel imellem, uanset CYP2C19 eller ABCB1genotypen.
English: Ticagrelor as well as the active metabolite are P-gp substrates.
Danish: Ticagrelor samt den aktive metabolit er P-gp-substrater.
English: Renal function should be checked after one month and thereafter according to routine medical practice, paying special attention to patients ≥ 75 years, patients with moderate/severe renal impairment and those receiving concomitant treatment with an ARB.
Danish: Nyrefunktionen bør kontrolleres efter én måned og derefter ifølge rutinemæssig medicinsk praksis, idet der udvises særlig opmærksomhed hos patienter ≥ 75 år, patienter med moderat/alvorligt nedsat nyrefunktion samt hos patienter, der er i samtidig behandling med en angiotensin II-receptorantagonist.
English: CALENDAR BLISTER (14 TABLETS)
Danish: Kalenderblister (14 tabletter)
English: A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from Possia therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Danish: Det skal besluttes, om amning skal ophøre eller behandling med Possia seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen.
English: Ticagrelor is also a P-gp substrate and a weak P-gp inhibitor and may increase the exposure of P-gp substrates.
Danish: Ticagrelor er desuden et P-gpsubstrat og en svag P-gp-hæmmer, som kan øge eksponeringen af P-gp-substrater.
English: Due to observations of mostly asymptomatic ventricular pauses in an earlier clinical study, patients with an increased risk of bradycardic events (e.g. patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree AV block or bradycardic-related syncope) were excluded from the main PLATO study evaluating the safety and efficacy of Possia.
Danish: Som følge af observationer af overvejende asymptomatiske ventrikulære pauser i et tidligere klinisk studie blev patienter med øget risiko for bradykardi-hændelser (f.eks. patienter uden en pacemaker som har syg sinus-knude, 2. eller 3. grads AV-blok eller bradykardi-relateret synkope) udelukket fra PLATO-hovedstudiet, der vurderede sikkerheden og effekt af Possia.
English: If you are not sure, talk to your doctor or pharmacist before taking Possia.
Danish: Hvis du er usikker, så tal med lægen eller apoteket, før du tager Possia.
English: Antifibrinolytic therapy (aminocaproic acid or tranexamic acid) and/or recombinant factor VIIa may increase haemostasis.
Danish: Antifibrinolytisk behandling (aminokapronsyre eller Cyklokapron) og/eller rekombinant faktor VIIa kan øge hæmostase.
English: Co-administration of ticagrelor with doses of simvastatin exceeding 40 mg daily could cause adverse effects of simvastatin and should be weighed against potential benefits.
Danish: Samtidig administration af ticagrelor og simvastatindoser på mere end 40 mg dagligt kan forårsage simvastatinbivirkninger og skal vejes op mod potentielle fordele.
English: The Cmax and AUC of the active metabolite were reduced by 89% and 56%, respectively.
Danish: Cmax og AUC for den aktive metabolit blev reduceret med hhv. 89 % og 56 %.
English: Co-administration of Possia and levonorgestrel and ethinyl estradiol increased ethinyl estradiol exposure approximately 20% but did not alter the pharmacokinetics of levonorgestrel.
Danish: Samtidig administration af Possia og levonorgestrel og ethinylestradiol øgede ethinylestradiols eksponering med ca. 20 %, men ændrede ikke farmakokinetikken for levonorgestrel.
English: Patients in PLATO receiving ticagrelor took a variety of statins, with no concern of an association with statin safety among the 93% of the PLATO cohort taking these medicinal products.
Danish: Patienter i PLATO, der fik ticagrelor, anvendte forskellige statiner, uden at dette blev sat i forbindelse med sikkerhedsproblemer ved statin hos de 93 % i PLATO-kohorten, der
English: This belongs to a group of medicines called
Danish: Lægemidlet tilhører en gruppe lægemidler, der kaldes blodfortyndende midler.
English: EU/1/10/656/005 168 film-coated tablets EU/1/10/656/006 100x1 film-coated tablets
Danish: EU/1/10/656/001 60 filmovertrukne tabletter EU/1/10/656/002 180 filmovertrukne tabletter EU/1/10/656/003 14 filmovertrukne tabletter EU/1/10/656/004 56 filmovertrukne tabletter EU/1/10/656/005 168 filmovertrukne tabletter EU/1/10/656/006 100x1 filmovertrukne tabletter
English: In rabbits a slight delay in hepatic maturity and skeletal development was seen in foetuses from dams at high dose without showing maternal toxicity (safety margin of 4.5).
Danish: Der blev hos kaniner set en ganske lille forsinkelse i hepatisk modenhed og skeletudvikling hos fostre fra moderdyr på høj dosis uden en indikation af toksicitet hos moderen (sikkerhedsmargin på 4,5).
English: The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human
Danish: Indehaveren af markedsføringstilladelsen skal udføre de lægemiddelovervågningsaktiviteter, som er beskrevet i lægemiddelovervågningsplanen (ifølge aftalen i RMP, modul 1.8.2 i markedsføringstilladelsen), og enhver efterfølgende opdatering af RMP, som er godkendt af Udvalget for Lægemidler til Mennesker (CHMP).
English: - sudden numbness or weakness of your arm, leg or face, especially if only on one side of the
Danish: - pludselig opstået følelsesløshed eller nedsat kraft i din arm, dit ben eller ansigtet, især
English: • non-steroidal anti-inflammatory drugs (abbreviated as NSAIDs) often taken as pain killers such as ibuprofen and naproxen.
Danish: • non-steroide antiinflammatoriske midler (forkortet NSAID) der ofte tages som smertestillende medicin, såsom ibuprofen og naproxen.
English: The formation of the major circulating metabolite AR-C124910XX (also active) from ticagrelor is rapid with a median tmax of approximately 2.5 hours.
Danish: Dannelsen af den vigtigste cirkulerende metabolit AR-C124910XX (også aktiv) fra ticagrelor er hurtig med en median tmax på ca. 2,5 timer.
English: The mechanism for the hepatic adenomas is likely due to a rodent-specific enzyme induction in the liver.
Danish: Mekanismen bag leveradenomer skyldes sandsynligvis gnaverspecifik enzyminduktion i leveren.
English: OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
Danish: C. ANDRE FORHOLD OG BETINGELSER FOR MARKEDSFØRINGSTILLADELSEN
English: Most reported symptoms of dyspnoea were mild to moderate in intensity, and most were reported as a single episode
Danish: De hyppigst rapporterede symptomer på dyspnø var milde til moderate i styrke, og de fleste blev rapporteret som en enkelt episode kort efter behandlingsstart.
English: Therefore, due to the limited clinical experience, Possia should be used with caution in these patients (see section 5.1).
Danish: Som følge af begrænset klinisk erfaring skal Possia anvendes med forsigtighed hos disse patienter (se pkt.
English: If a patient is to undergo elective surgery and antiplatelet effect is not desired, Possia should be discontinued 7 days prior to surgery (see section 5.1).
Danish: For patienter, der skal have foretaget elektiv kirurgi, og hvor en trombocythæmmende effekt ikke ønskes, skal Possia seponeres 7 dage før operationen (se pkt.
English: Ticagrelor produced irregular cycles (mostly extended cycles) in female rats, but did not affect overall fertility in male and female rats.
Danish: Ticagrelor gav uregelmæssige cyklusser (hovedsageligt forlængede cyklusser) hos hunrotter, men påvirkede ikke den overordnede fertilitet hos han- og hunrotter.
English: For Possia, 0.9% of patients discontinued study drug because of dyspnoea compared with 0.1% taking clopidogrel.
Danish: For Possia ophørte 0,9 % af patienterne med forsøgsmedicinen på grund af dyspnø sammenlignet med 0,1 %, der tog clopidogrel.
English: As a precautionary measure, the use of ticagrelor in patients with uric acid nephropathy is discouraged.
Danish: Som en sikkerhedsforanstaltning frarådes brugen af ticagrelor hos patienter med urinsyre-nefropati.
English: Co-administration of Possia with tolbutamide resulted in no change in the plasma levels of either medicinal product, which suggest that ticagrelor is not a CYP2C9 inhibitor and unlikely to alter the CYP2C9 mediated metabolism of medicinal products like warfarin and tolbutamide.
Danish: Samtidig administration af Possia og tolbutamid resulterede ikke i en ændring af plasmaniveauerne for de to lægemidler, hvilket indikerer at ticagrelor ikke er en CYP2C9-hæmmer og med stor sandsynlighed ikke vil ændre den CYP2C9-medierede metabolisme af lægemidler som warfarin og tolbutamid.
English: Name and address of the manufacturer(s) responsible for batch release
Danish: Navn og adresse på fremstilleren (fremstillerne) ansvarlig(e) for batchfrigivelse
English: In addition, caution should be exercised when administering Possia concomitantly with medicinal products known to induce bradycardia.
Danish: Der skal desuden udvises forsigtighed, når Possia administreres samtidig med lægemidler, der er kendt for at inducere bradykardi.
English: Following an initial dose of ASA, Possia should be used with a maintenance dose of ASA of 75-150 mg (see
Danish: Efter en initialdosis ASA bør Possia anvendes sammen med en vedligeholdelsesdosis på 75-150 mg ASA (se pkt.
English: In patients with Acute Coronary Syndromes (ACS), premature discontinuation with any antiplatelet therapy, including Possia, could result in an increased risk of cardiovascular death, or myocardial infarction due to the patient's underlying disease.
Danish: Hos patienter med akut koronarsyndrom (AKS) kan præmatur seponering af en antitrombotisk behandling, herunder Possia, resultere i øget risiko for kardiovaskulært dødsfald eller myokardieinfarkt som følge af patientens tilgrundliggende sygdom.
English: Discuss with your doctor if you notice any of the following:
Danish: Drøft det med lægen, hvis du bemærker en eller flere af følgende bivirkninger:
English: • The active substance is ticagrelor.
Danish: • Aktivt stof: ticagrelor.
English: Ingestion of a high-fat meal resulted in a 21% increase in ticagrelor AUC and 22% decrease in the active metabolite Cmax but had no effect on ticagrelor Cmax or the AUC of the active metabolite.
Danish: Indtagelse af et måltid med højt fedtindhold resulterede i en 21 % forøgelse af ticagrelors AUC og en 22 % reduktion af den aktive metabolits Cmax, men havde ingen indvirkning på ticagrelors Cmax eller AUC for den aktive metabolit.
English: In clinical pharmacology studies, the exposure (Cmax and AUC) to ticagrelor in Japanese subjects was approximately 40% (20% after adjusting for body weight) higher compared to that in Caucasians.
Danish: I kliniske farmakologistudier var eksponeringen (Cmax og AUC) for ticagrelor hos japanske forsøgspersoner ca. 40 % (20 % efter justering for kropsvægt) højere sammenlignet med eksponeringen hos kaukasiske forsøgspersoner.
English: What you need to know before you take Possia
Danish: Det skal du vide, før du begynder at tage Possia
English: Fatal CABG bleeding occurred in 6 patients in each treatment group (see section 4.4).
Danish: Der forekom fatal koronar bypass-blødning hos 6 patienter i hver behandlingsgruppe (se pkt.
English: The primary route of ticagrelor elimination is via hepatic metabolism.
Danish: Den primære udskillelsesvej for ticagrelor er via metabolisme i leveren.
English: More patients had ventricular pauses with ticagrelor (6.0%) than with clopidogrel (3.5%) in the acute phase; and 2.2% and 1.6% respectively after 1 month (see section 4.4).
Danish: Der var flere patienter der havde ventrikulære pauser med ticagrelor (6,0 %) end med clopidogrel (3,5 %) i den akutte fase; og hhv. 2,2 % og 1,6 % efter 1 måned (se pkt.
English: Intracranial bleeding: There were more intracranial non-procedural bleeds with ticagrelor (n=27 bleeds in 26 patients, 0.3%) than with clopidogrel (n=14 bleeds, 0.2%), of which 11 bleeds with ticagrelor and 1 with clopidogrel were fatal.
Danish: Intrakraniel blødning: Der var flere intrakranielle ikke-procedurerelaterede blødninger med ticagrelor (n=27 blødninger hos 26 patienter, 0,3 %) end med clopidogrel (n=14 blødninger, 0,2 %), hvoraf 11 blødninger med ticagrelor og 1 med clopidogrel var fatale.
English: CABG-related bleeding: In PLATO, 42% of the 1584 patients (12% of cohort) who underwent coronary artery bypass graft (CABG) surgery had a PLATO Major Fatal/Life-threatening bleeding with no difference between treatment groups.
Danish: 42 % af de 1584 patienter (12 % af kohorten) i PLATO, der fik foretaget koronar bypassoperation (CABG), havde en PLATO Major Fatal/Life-threatening bleeding uden forskel behandlingsgrupperne imellem.
English: Your doctor will tell you how much to take (usually between
Danish: Din læge vil fortælle dig, hvor meget du skal tage (sædvanligvis 75-150 mg dagligt).
English: Medicinal products known to induce bradycardia
Danish: Lægemidler, der er kendt for at inducere bradykardi
English: The metabolite parent ratios are 0.28 for Cmax and 0.42
Danish: Metabolit/stamform-forholdet er 0,28 for Cmax og 0,42 for AUC.
English: Ask your pharmacist how to throw away medicines you no longer use .
Danish: Spørg på apoteket, hvordan du skal bortskaffe medicinrester.
English: Compared with clopidogrel, patients with asthma/COPD treated with ticagrelor may have an increased risk of experiencing non-serious dyspnoea (3.29% ticagrelor versus 0.53% clopidogrel) and serious dyspnoea (0.38% ticagrelor versus 0.00% clopidogrel).
Danish: Ved sammenligning med clopidogrel kan patienter med astma/KOL, som blev behandlet med ticagrelor, have en øget risiko for at få ikke-alvorlig dyspnø (3,29 % ticagrelor versus 0,53 % clopidogrel) og alvorlig dyspnø (0,38 % ticagrelor versus 0,00 % clopidogrel).
English: Patients with asthma/COPD may have an increased absolute risk of experiencing dyspnoea with Possia (see section 4.8).
Danish: Patienter med astma/KOL kan have en øget absolut risiko for at få dyspnø under behandling med Possia (se pkt.
English: In the phase 3 pivotal trial (PLATO [PLATelet Inhibition and Patient Outcomes], 18,624 patients) key exclusion criteria included an increased risk for bleeding, clinically important thrombocytopenia or anaemia, previous intracranial bleed, gastrointestinal bleed within the past 6 months or major surgery within the past 30 days.
Danish: I det afgørende fase 3-studie (PLATO, [PLATelet Inhibition and Patient Outcomes], 18.624 patienter) omfattede de centrale eksklusionskriterier en øget blødningsrisiko, klinisk væsentlig trombocytopeni eller anæmi, tidligere intrakraniel blødning, gastrointestinal blødning inden for de sidste 6 måneder eller større kirurgiske indgreb inden for de sidste 30 dage.
English: Few patients in PLATO had fatal bleeds: 20 (0.2%) for ticagrelor and 23 (0.3%) for clopidogrel (see section 4.4).
Danish: Der var få patienter i PLATO, der havde fatale blødninger: 20 (0,2 %) for ticagrelor og 23 (0,3 %) for clopidogrel (se pkt.
English: Other clinically meaningful adverse reactions which may occur with overdose include dyspnoea and ventricular pauses (see section 4.8).
Danish: Andre klinisk betydningsfulde bivirkninger, der kan forekomme ved overdosering, inkluderer dyspnø og ventrikulære pauser (se pkt.
English: If you stop taking Possia, it may increase your chances of having another heart attack or stroke or dying from a disease related to your heart or blood vessels.
Danish: Hvis du stopper med at tage Possia, kan det øge risikoen for, at du får et til hjerteanfald eller slagtilfælde, eller at du dør af en sygdom i hjertet eller blodkarrene.
English: Patients treated with clopidogrel can be directly switched to Possia if needed (see section 5.1).
Danish: Patienter, der behandles med clopidogrel, kan om nødvendigt skifte direkte over til Possia (se pkt.
English: The totality of renal AEs reported were 4.9% for ticagrelor vs. 3.8% for clopidogrel, however a similar percent of patients reported events considered by the investigators as causally related to treatment; 54 (0.6%) for ticagrelor and 43 (0.5%) for clopidogrel.
Danish: I alt blev der hos 4,9 % af ticagrelorpopulationen indberettet nyrerelaterede hændelser vs. hos 3,8 % af clopidogrel-populationen, dog var det en sammenfaldende procentdel af patienterne, der indberettede hændelser, som investigatorerne vurderede som kausalt relateret til behandlingen; 54 (0,6 %) for ticagrelor og 43 (0,5 %) for clopidogrel.
English: Age, sex, weight, race, geographic region, concurrent conditions, concomitant therapy, and medical history, including a previous stroke or transient ischaemic attack, all did not predict either overall or non-procedural PLATO Major bleeding.
Danish: Hverken alder, køn, vægt, etnicitet, geografisk region, comorbiditet, samtidig behandling eller anamnese, herunder tidligere apopleksi og transitorisk iskæmisk attak, kunne prædiktere de samlede eller de ikke-procedurerelaterede PLATO-definerede 'Major bleedings'.
English: Clinical pharmacology interaction studies showed that co-administration of ticagrelor with heparin, enoxaparin and ASA or desmopressin did not have any effect on the pharmacokinetics of ticagrelor or the active metabolite or on ADP-induced platelet aggregation compared with ticagrelor alone.
Danish: Kliniske farmakologiske interaktionsstudier viste, at samtidig administration af ticagrelor og heparin, enoxaparin og ASA eller desmopressin ikke havde nogen indvirkning på ticagrelors eller den aktive metabolits farmakokinetik eller på ADP-induceret trombocytaggregation sammenlignet med ticagrelor alene.
English: In female rats, ticagrelor at high dose showed an increased incidence of uterine tumors (adenocarcinomas) and an increased incidence of hepatic adenomas.
Danish: Ticagrelor i høje doser til hunrotter viste en øget incidens af uterine tumorer (adenokarcinomer) og en øget incidens af leveradenomer.
English: A combined efficacy and safety composite (CV death, MI, stroke, or PLATO-defined ‘Total Major' bleeding) indicates that the benefit in efficacy of Possia compared to clopidogrel is not offset by the major bleeding events (ARR 1.4%, RRR 8%, HR 0.92; p=0.0257) over 12 months after ACS.
Danish: En kombineret virknings- og sikkerhedsprofil (kardiovaskulære dødsfald, MI, apopleksi eller PLATO-defineret "Total Major" blødning) indikerer, at fordelen ved Possias virkning sammenlignet med clopidogrels ikke udlignes af de alvorlige blødningshændelser (ARR 1,4 %, RRR 8 %, HR 0,92; p=0,0257) gennem 12 måneder efter AKS.
English: The increase in Holter-detected ventricular pauses with ticagrelor was higher in patients with chronic heart failure (CHF) than in the overall study population during the acute phase of ACS, but not at one month with ticagrelor or compared to clopidogrel.
Danish: Stigningen i Holter-påviste ventrikulære pauser med ticagrelor var større hos patienter med kronisk hjerteinsufficiens (CHF) end hos den samlede studiepopulation i den akutte fase af AKS, men ikke efter en måneds behandling med ticagrelor eller i forhold til clopidogrel.
English: Major Fatal/Life-threatening Bleed: Clinically apparent with >50 g/l decrease in haemoglobin or ≥4 red cell units transfused; or fatal; or intracranial; or intrapericardial with cardiac tamponade; or with hypovolaemic shock or severe hypotension requiring pressors or surgery.
Danish: Major Fatal/Life-threatening Bleed: Klinisk åbenbar med en reduktion på >50 g/l af hæmoglobin eller ≥4 infunderede erytocytenheder ; eller fatal; eller intrakraniel; eller intraperikardiel med hjertetamponade; eller med hypovolæmisk shock eller svær hypotension, der kræver pressorstoffer eller operation.
English: Based on a relationship observed in PLATO between maintenance ASA dose and relative efficacy of ticagrelor compared to clopidogrel, co-administration of Possia and high maintenance dose ASA (>300 mg) is not recommended (see section 5.1).
Danish: Baseret på et forhold observeret i PLATO mellem vedligeholdelsesdosis af ASA og relativ effekt af ticagrelor sammenlignet med clopidogrel bør Possia ikke administreres samtidig med høje vedligeholdelsesdoser af ASA (>300 mg) (se pkt.
English: Talk to your doctor before taking Possia if you are breast-feeding.
Danish: Tal med din læge, før du tager Possia, hvis du ammer.
English: Dyspnoea adverse events ( AEs) (dyspnoea, dyspnoea at rest, dyspnoea exertional, dyspnoea paroxysmal nocturnal and nocturnal dyspnoea), when combined, was reported by 13.8% of patients treated with ticagrelor and by 7.8% of patients treated with clopidogrel.
Danish: Dyspnø-relaterede bivirkninger (kombination af dyspnø, dyspnø i hvile, anstrengelsesudløst dyspnø, paroksystisk natlig dyspnø og natlig dyspnø) blev indberettet af 13,8 % af de patienter, der blev behandlet med ticagrelor og af 7,8 % af de patienter, der blev behandlet med clopidogrel.
English: These differences are not considered clinically significant.
Danish: Forskellene anses ikke for klinisk signifikante.
English: • Simvastatin - Co-administration of ticagrelor with simvastatin increased simvastatin Cmax by 81% and AUC by 56% and increased simvastatin acid Cmax by 64% and AUC by 52% with some individual increases equal to 2 to 3 fold.
Danish: • Simvastatin - Samtidig administration af ticagrelor og simvastatin øgede simvastatins Cmax med 81 % og AUC med 56 % og øgede simvastatinsyres Cmax med 64 % og AUC med 52 % med nogle enkeltstående forøgelser svarende til det dobbelte og tredobbelte.
English: Creatinine levels may increase during treatment with Possia (see section 4.8).
Danish: Kreatininniveauerne kan blive forhøjet under behandling med Possia (se pkt.
English: Other
Danish: Andet
English: Therefore, appropriate clinical and/or laboratory monitoring is recommended when giving narrow therapeutic index P-gp dependent medicinal products like digoxin or cyclosporin concomitantly with Possia (see section 4.4).
Danish: Relevant klinisk og/eller laboratoriemæssig monitorering anbefales derfor, når der gives P-gp-afhængige lægemidler med et snævert terapeutisk indeks såsom digoxin eller ciclosporin samtidig med Possia (se pkt.
English: (%/yr)
Danish: ARRa (%/år)
English: Co-administration may lead to a substantial increase in Possia exposure (see section 4.5).
Danish: Samtidig administration kan føre til en væsentlig forøgelse af eksponering for Possia (se pkt.
English: Marketing Authorisation Holder and Manufacturer
Danish: Indehaver af markedsføringstilladelsen og fremstillere